<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; King Pharmaceuticals</title>
	<atom:link href="http://www.stockbloghub.com/tag/king-pharmaceuticals/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(KG) ZymoGenetic&#8217;s Arthritis Drug Disappoints</title>
		<link>http://www.stockbloghub.com/2009/09/11/kg-zymogenetics-arthritis-drug-disappoints/15016</link>
		<comments>http://www.stockbloghub.com/2009/09/11/kg-zymogenetics-arthritis-drug-disappoints/15016#comments</comments>
		<pubDate>Fri, 11 Sep 2009 22:47:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15016</guid>
		<description><![CDATA[Yesterday, ZymoGenetics Inc (ZGEN) announced that its rheumatoid arthritis drug Atacicept, failed to reach its goal of controlling the disease in mid-stage studies. The data did not support a direct move to late-stage trials. However, the study confirmed the biological effect of Atacicept, and did not display any unexpected side effects. Atacicept is being developed in collaboration with Merck Serono S.A. (formerly Serono S.A.), an affiliate of Merck KGaA, Darmstadt, Germany.  Under this agreement, ZymoGenetics will co-promote Atacicept with Merck Serono in the US, while Merck Serono will promote Atacicept ex-US. In view of the disappointing results, Merck Serono has not decided whether the late-stage trials will be conducted. Atacicept is also being developed for other indications such as lupus and multiple sclerosis. As a reminder, Recombinant human thrombin (rhThrombin, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/kg-zymogenetics-arthritis-drug-disappoints/15016/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) FDA Advisory Panel to Review Acurox</title>
		<link>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484</link>
		<comments>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484#comments</comments>
		<pubDate>Fri, 04 Sep 2009 22:54:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACUR]]></category>
		<category><![CDATA[Acura Pharmaceuticals Inc.]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14484</guid>
		<description><![CDATA[King Pharmaceuticals, Inc. (KG) and Acura Pharmaceuticals, Inc. (ACUR) recently met with the U.S. Food and Drug Administration (FDA) to discuss the agency’s response to the New Drug Application (NDA) for Acurox (oxycodone HCl and niacin). The companies and the agency agreed that the NDA should be reviewed by an FDA advisory committee. The agency has not asked the companies to conduct additional clinical trials. Acurox is an orally administered immediate release tablet containing oxycodone HCl as an active analgesic ingredient, niacin as an active ingredient in subtherapeutic amounts, and a unique combination of other ingredients. King and Acura are looking to gain approval of Acurox for the relief of moderate-to-severe pain. Acurox is also designed to discourage some common methods of misuse and abuse. In its complete response letter, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/kg-fda-advisory-panel-to-review-acurox/14484/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CP) ZymoGenetics Files Against King Pharma</title>
		<link>http://www.stockbloghub.com/2009/08/21/cp-zymogenetics-files-against-king-pharma/13160</link>
		<comments>http://www.stockbloghub.com/2009/08/21/cp-zymogenetics-files-against-king-pharma/13160#comments</comments>
		<pubDate>Sat, 22 Aug 2009 03:11:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Railroads]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Canadian Pacific Railway Limit]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13160</guid>
		<description><![CDATA[ZymoGenetics, Inc. (ZGEN) has filed a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA) requesting the agency to remove King Pharmaceuticals’ (KG) Thrombin-JMI from the market in the interest of patient safety. ZymoGenetics filed the CP based on reports of serious or fatal bleeding-related adverse events in surgical patients exposed to bovine (cattle-derived) thrombin. Thrombin-JMI is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible. The source material for Thrombin-JMI comes from bovine plasma and lung tissue. The treatment is a key product in King’s portfolio. For the twelve months ended December 31, 2008, Thrombin-JMI accounted for 16.3% of total revenues. As such, the removal of the product from the market would be a major blow for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/21/cp-zymogenetics-files-against-king-pharma/13160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KG) King Pharmaceuticals &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2009/08/20/king-pharmaceuticals-bear-of-the-day/12853</link>
		<comments>http://www.stockbloghub.com/2009/08/20/king-pharmaceuticals-bear-of-the-day/12853#comments</comments>
		<pubDate>Thu, 20 Aug 2009 17:47:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12853</guid>
		<description><![CDATA[King Pharmaceuticals (KG) reported second quarter results of -32 cents per share, beating the Zacks Consensus Estimate of -38 cents per share. Although revenues increased 12% from the year-ago period, we remain concerned about the declining prescription trends of most of the company&#8217;s key products. Moreover, King faced several regulatory setbacks and is yet to gain approval for its key pipeline candidate, Embeda. The delay in Embeda&#8217;s approval has been frustrating and we expect investor focus to remain on this event. While King is optimistic about gaining approval for Embeda later this year, non-approval would be a major blow. Pipeline setbacks Incorporatedreasing competition, generic threats and declining prescription trends are likely to weigh on the stock. We have an Underperform rating on the stock. Zacks Investment Research View original at: ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/king-pharmaceuticals-bear-of-the-day/12853/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

